Biogen has announced it will give up ownership and halt sales of Aduhelm, an embattled Alzheimer's disease drug that was scrutinized following its 2021 approval. Biogen said it terminated a ...

Here we go again. With Aduhelm largely sidelined, Biogen and Eisai are hoping for a better fortunes with their next Alzheimer's disease therapy lecanemab, which is now fully filed with the FDA.

After months of debate about the validity of its phase 3 clinical trials for Alzheimer's therapy Aduhelm, Biogen has published the results in a peer-review journal, allowing physicians to look at ...

This investigative series explores the science, money and politics behind the approval of the Alzheimer’s drug aducanumab. Read to learn more about this controversial drug and its implications ...